期刊文献+

健择对人鼻咽癌细胞系放射增敏机制的实验研究 被引量:6

Empirical Studies on Gemcitabine as a Mechanism of Radiosensitization in Human Nasopharyngeal Carcinoma Cell Line
下载PDF
导出
摘要 目的:观察单纯放射及放射联合健择(gemcitabine)对人鼻咽癌细胞系(CNE-2)细胞周期改变的影响,探讨健择对CNE-2细胞的放射增敏机制。方法:用流式细胞仪技术分析60Coγ射线单纯照射和照射联合健择对CNE-2细胞周期的影响。结果:单纯照射导致CNE-2细胞G1期阻滞,照射剂量<6Gy时与照射剂量呈正相关,>6Gy时G1期阻滞基本稳定在一定水平。5mg/L、10mg/L、15mg/L健择与CNE-2细胞共育24h后照射2Gy,以S期阻滞为主;随着单次照射剂量的提高,以G1阻滞明显。CNE-2细胞与健择15mg/L共育12h后照射2Gy,开始时以G1阻滞为主,但24h后以S期阻滞明显,且至少维持36h以上。结论:健择对CNE-2细胞有中度放射增敏作用;其机制可能与健择引起S期或G1期阻滞有关。 Objective: To analyze the radiosensitization effect of gemcitabine in human nasopharyngeal carcinoma cell line CNE-2 in vitro. Methods: Flow cytometry was used to observe the effect on cell-cycle of γ-irradiation in conjunction with gemcitabine on CNE-2 cells. Results: Irradiation resulted in G1 block in a dose-dependent (〈6 Gy) manner. Concentrations of 5 mg/L, 10mg/L, or 15 mg/L gemcitabine were incubated with CNE-2 cells for 24h prior to irradiation with 2 Gy, resulting in significant S-phase block. G1 block was observed following increased doses of irradiation. 15nmol/L gemcitabine was incubated with CNE-2 for 12h prior to 2 Gy irradiation, resulting in an immediate G1 block that switched to an S-phase block after 24h and that lasted for at least 36 h. Conclusion: Radiosensitization of gemcitabine in CNE-2 cells is associated with induction of S-phase and/or G1 block.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2006年第13期734-737,共4页 Chinese Journal of Clinical Oncology
基金 广西壮族自治区教育厅科研基金项目资助(编号:Z2003-12)
关键词 健择 辐射增敏药 细胞周期 流式细胞术 人鼻咽癌细胞系 Gemcitabine Flow cytometry Radiation-sensitizing agents CNE cell line Cell cycle
  • 相关文献

参考文献9

  • 1Ostruszka LJ,Shewach DS.The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine[J].Cancer Res,2000,60(21):6080~6088
  • 2Halm U,Schumann T,Schiefke I,et al.Decrease of CA 19-9during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer[J].Br J Cancer,2000,2(5):1013~1016
  • 3Dalbagni G,Russo P,Sheinfeld J.Phase Ⅰ trial of intravesical gemcitabine in bacillus-calmette-Guerin-refractory transitional cell carcinoma of the bladder[J].J Clin Oncol,2002,20(15):3193~3198
  • 4Hertel LW,Boder GB,Kroin JS,et al.Evaluation of the antitumor activity of gemcitabine[J].Cancer Res,1990,50 (14):4417 ~4422
  • 5Burris HA,Moore MJ,Andersen J,et al.Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J].J Clin Oncol,1997,15(6):2403~2413
  • 6Shewach DS,Hahn TM,Chang E,et al.Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells[J].Cancer Res,1994,54(12):3218~3223
  • 7Kotchetkov R,Groschel B,Gmeiner WH,et al.Antineoplastic activity of a novel multimeric gemcitabine-monophosphate prodrug against thyroid cancer cells in vitrol[J].Anticancer Res,2000,20(5A):2915~2922
  • 8Meek DW,Street AJ.Nuclear protein phosphorylation and growth control[J].Biochem J,1992,287(1):1~15
  • 9Rosier JF,Beauduin M,Bruniaux M,et al.The effect of 2'-2' difluorodeoxycytidine (dFdC,gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity[J].Int J Radiat Biol,1999,75(2):245~251

同被引文献45

引证文献6

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部